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Dendritic cells (DCs) are specialized antigen presenting cells of bone marrow origin that
can exist in tissues in either an immature or mature state. DCs have a myriad of roles in
immunity and tolerance induction, but are perhaps best known for their role in the activa-
tion and differentiation of naïveT cells at the onset of an acquired immune response. Over
the past decade, a body of literature has developed that suggests that DCs, as well as
many other myeloid cell populations, are also capable of exerting “regulatory” effects onT
cell responses. However, relatively little is known regarding the mechanisms by which such
regulatory myeloid cells arise in vivo. In this mini-review, we first define the characteristics
of “regulatory” DCs (rDCs) and then focus on the contribution of non-hematopoietic stro-
mal cells to their generation within specific tissue microenvironments. We also highlight
areas of research that warrant future attention, arguing for a focusing of efforts toward a
better understanding of the features of stromal cell populations that enable the induction
of rDCs. Finally, we discuss how an understanding of stromal cell-myeloid cell interactions
may lead to new therapeutic strategies for cancer, autoimmunity, and infectious disease.
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INTRODUCTION
Dendritic cells (DCs) lie at the interface of innate and adaptive
immunity, playing a critical role in the initiation of effective T
cell-mediated immune responses. Paradoxically, DCs also have
the potential to exert powerful negative regulatory effects on the
immune system (Steinman et al., 2003). This potential for damp-
ening immunity has spawned great interest in the context of cell-
based therapeutic intervention in a variety of autoimmune and
inflammatory contexts (Kalantari et al., 2011). Alongside several
populations of conventional CD11chi DCs (cDCs), there are many
other myeloid cell populations capable of antigen presentation and
exerting both positive and negative effects on T cell responses. This
has given rise to a literature that contains a significant level of con-
fusion. That many of these myeloid cells also share phenotypic
characteristics has only compounded the problem. For example,
the assignment of cells as DCs based solely on CD11c expression
has not always been helpful (Drutman et al., 2012). The relation-
ship between cDCs and other myeloid cells is further complicated
by the existence of convergent differentiation pathways, partic-
ularly under inflammatory conditions (Geissmann et al., 2010).
Nevertheless, recent data strongly support the concept that cDCs
belong to a distinct immune cell lineage (Meredith et al., 2012;
Satpathy et al., 2012). The identification of key lineage-related
transcription factors should allow rapid progress in determining
the relationships between cDCs and other myeloid cell popula-
tions and add some clarity to studies of the regulatory properties
of these cells.
Whilst the regulatory potential of cDCs in vivo has long
been appreciated (Hawiger et al., 2001), consensus regarding the
phenotypic features of cDCs and myeloid cells with regulatory
properties has been hard to reach. Historically, “immature” cDCs
were classed as those that had yet to receive a pathogen-derived
signal and existed in the tissues in a state of readiness for antigen
presentation, with high levels of endocytosis to facilitate antigen
capture and large intracellular pools of MHCII. Upon pathogen
recognition by TLRs or other pattern recognition receptors, cDCs
“mature” and in so doing, shut down endocytosis in favor of
MHCII-peptide display, heightened expression of co-stimulatory
molecules, and the secretion of cytokines that direct naïve T cell
differentiation. Early literature suggested that immature cDCs may
also be endowed with regulatory function, although this may
represent an oversimplification (Kleindienst et al., 2005). Con-
versely, all subsets of splenic cDC have recently been shown to
be capable of producing the regulatory cytokine IL-10, even after
TLR induced maturation (Maroof and Kaye, 2008; Owens et al.,
2012). In the context of chronic Leishmania donovani infection,
IL-10-producing cDCs are capable of antigen presentation and the
induction of naïve T cell proliferation in vitro (Owens et al., 2012),
making them functionally distinct from rDCs as we define below.
Against this background, where pleiotropic function character-
izes cDCs, it becomes pertinent to ask whether there are distinct
populations of DCs (regulatory DCs; rDCs) in which regulatory
function is hardwired, and how stromal cell populations can con-
tribute to their generation (Figure 1). The remainder of this review
will focus on addressing this question.
REGULATORY DCs: CHARACTERIZATION AND FUNCTION
Amongst cytokines, IL-10 has become synonymous with the con-
cept of regulation, yet as discussed above cDCs under appropriate
circumstances are quite capable of producing this cytokine. Hence,
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FIGURE 1 | Relationships between rDCs and cDCs. cDCs are known to
originate from a hematopoietic stem cell precursor, through a sequence of
events (not shown) that culminates in production of tissue precursor cells
(pre-cDCs). In tissue, cDCs exist as immature cells, but functionally mature
in response to microbial sensing mediated through various pattern
recognition receptors (PRRs). Mature cDCs have an enhanced capacity to
prime naïve T cells and induce their differentiation (shown here for Th1
cells). Mature cDCs may also help terminate excessive T cell responses by
inducing a “self regulatory” phenotype, e.g., through the induction of IL-10
production by Th1 cells. Under steady state conditions, stromal cells (blue)
are able to induce the generation of IL-10 and PGE2-producing rDCs from
c-kit+ progenitors by production of PGE2, IL-6, and IL-10, as well as direct
interactions mediated by Fibronectin. During the chronic inflammation
associated with L. donovani infection, IL-10-producing rDC generation is
enhanced by the production of CCL8 and CXCL12 by splenic stromal cells
that in many cases are directly parasitized (red). The stage(s) of
development at which cDCs or their precursors are able to differentiate into
regulatory DCs is not yet defined. Functionally, regulatory DCs are best
defined by their capacity to inhibit the proliferative capacity of T cells. rDCs
employ multiple mechanisms to suppress naïve T cell proliferation, including
the direct production of IL-10 and the induction of FoxP3+ nTreg and IL-10+
Tr1 Treg populations.
IL-10 alone could not be a sufficient criterion by which to distin-
guish rDCs. Although there is evidence of a rDC population with
functions that are distinct from cDCs, there is currently nothing
known as to the extent of plasticity within this group of myeloid
cells. In particular it is not yet clear whether rDCs represent a
terminally differentiated DC phenotype, or a transient functional
state reflecting phenotypic changes of myeloid cells in distinct tis-
sue microenvironments. Despite such ambiguity in the nature of
rDCs, some of the strongest evidence in support of the existence
of this population has come from the study of how fibroblasts and
endothelial cells impact on DC development from hematopoietic
stem cells or committed myeloid progenitors.
Stromal cell induction of rDC differentiation can occur in
multiple tissues even in the absence of pathogen recognition
and inflammation, suggesting that this is a normal homeostatic
process. To date, stromal cell-induced rDCs have been reported in
murine spleen (Svensson et al., 2004; Zhang et al., 2004; Tang et al.,
2006; Nguyen Hoang et al., 2010; Xu et al., 2012), liver (Xia et al.,
2008), kidney (Huang et al., 2009), lung (Li et al., 2008), and tumor
tissue (Liu et al., 2009). Despite their divergent tissue localiza-
tion, the majority of studies reporting stromal cell-induced rDCs
have characterized them as populations of CD11clo MHCIIlo/int
CD11b+cells, based on surface protein expression assessed by
flow cytometry. Splenic rDCs have also been reported to express
CD45RB (Wakkach et al., 2003; Svensson et al., 2004), although
the functional significance of this is not known. Expression of
co-stimulatory molecules such as CD40, CD80, and CD86 is gen-
erally lower on rDCs than cDCs, suggesting an impaired capacity
to deliver activatory signals to naïve T cell populations, although
high co-stimulatory molecule expression (particularly CD80) by
rDCs has been reported in some contexts (reviewed by Svensson
and Kaye, 2006).
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Several other characteristics of stromal cell-induced rDCs
allow for their more rigorous identification. Multiple studies have
reported that rDCs are major producers of the anti-inflammatory
cytokine IL-10, including those from spleen (Svensson et al., 2004;
Zhang et al., 2004; Tang et al., 2006), liver (Xia et al., 2008), kid-
ney (Huang et al., 2009), and lung (Li et al., 2008), suggesting
that IL-10 production is a conserved feature of rDCs, irrespec-
tive of tissue localization, or origin. This preferential IL-10 pro-
duction can be driven by TLR triggering, and at least partially
relies on ERK signaling (Qian et al., 2006). However, conven-
tional CD11chiMHCIIhicDCs are also capable of abundant IL-10
production (Saraiva and O’Garra, 2010), a process particularly
pronounced during chronic parasitic infection (Maroof and Kaye,
2008; Owens et al., 2012) indicating that IL-10 production is not
unique to rDCs.
Distinctive functional properties of rDCs provide perhaps the
best method for their identification, as rDCs utilize multiple path-
ways in order to exert their immune regulatory function. Several
reports suggest that rDCs are capable of modulating T cell prolif-
eration in vitro and in vivo, with splenic stromal-induced rDCs
suppressing proliferation via IL-10, TGFβ, and/or nitric oxide
(NO) production (Svensson et al., 2004; Zhang et al., 2004; Tang
et al., 2006), and pulmonary stromal-induced rDCs inhibiting T
cell proliferation via production of Prostaglandin-E2 (PGE2; Li
et al., 2008). Importantly this capacity for stromal-induced rDCs
to suppress T cell proliferation does not appear to be dependent on
the presence of stromal cells within the assays, as stromal-induced
rDCs are capable of suppressing T cell proliferation during in vitro
co-culture solely with T cells, as well as after adoptive transfer
in vivo. This therefore indicates a regulatory process distinct from
that recently reported for lymph node (LN) fibroblastic reticular
cells (FRCs), whereby nitric oxide produced by LN FRCs regu-
lates T cell proliferation via direct effects on T cells, in addition
to modulating cDC function (Khan et al., 2011; Lukacs-Kornek
et al., 2011; Siegert et al., 2011). Stroma-induced rDCs within
tumors are able to utilize an alternative mechanism involving the
direct production of Arginase-1 (Liu et al., 2009). This results in
the metabolism of l-Arginine and consequent suppression of T
cell proliferation in vitro and in vivo. In contrast, splenic stroma-
induced rDCs specifically recruit CXCR3+ Th1 cells to more
efficiently suppress their proliferation, via the IFNα/β-dependent
production of IP-10 after TLR triggering (Qian et al., 2007). More
recent evidence has suggested that splenic rDCs are also able to
directly induce apoptosis of activated CD4+ T cells by a process
involving NO, Fas-Ligand, and IFNγ (Xu et al., 2012), a mech-
anism also reported to occur in the liver (Xia et al., 2008). This
capacity for direct suppression of CD4+ T cell proliferation, even
after TLR induced “maturation,” is a cardinal feature of rDCs that
allows for them to be distinguished from cDCs.
In addition to their direct modulatory effects on activated T
cells, rDCs can also employ indirect immune regulatory mecha-
nisms, in many cases by the induction of specialized populations
of regulatory T cells (Treg). Splenic stroma-induced rDCs directly
induce IL-10-producing Tr1 Treg in vitro (Svensson et al., 2004),
whereas rDCs induced by pulmonary stromal cells can induce
populations of Foxp3+ natural Treg (Li et al., 2008). Whether the
differential induction of Treg populations from rDCs induced by
stromal cells of distinct tissues reflects the polarization of rDC
subsets is currently unclear. It will be important to define stroma-
induced rDCs from distinct tissues in more detail to elucidate
whether further functional subsets exist, in addition to the cues
that drive their differentiation. However, Treg induction by rDCs
does not always contribute to their regulatory potential (Tang et al.,
2006) and indeed rDCs have been reported to activate NK cells in
some circumstances (Qian et al., 2006). These divergent functions
suggest that although rDCs are capable of suppressing the cellular
components of an active immune response, in different contexts
rDCs may also act in an immune stimulatory fashion.
Taking these multiple parameters into consideration, a “min-
imal” definition of stromal-induced rDCs can be reached as
CD11clo/int MHCIIlo/int CD11b+ myeloid cells, capable of IL-10
production, the direct suppression of CD4+ T cell proliferation
and (in some cases) the induction of Treg. Although several other
functional features can also contribute to the identification or
characterization of rDCs, these are either tissue-context depen-
dent, or have not yet been assessed in all stromal-induced rDC
populations.
SPECIFIC CONTEXTS LEADING TO THE INDUCTION OF rDCs
BY STROMAL CELLS
It is clear that in several tissue contexts stromal cells can induce
rDCs, but direct evidence as to whether this process is regulated
by infection or inflammation is more limited. One exception is
experimental visceral leishmaniasis (EVL), a chronic infection
caused by the intracellular parasite L. donovani (Kaye et al., 2004).
Splenic stromal cells from mice infected with L. donovani have
an enhanced capacity to direct hematopoietic progenitors toward
a rDC phenotype in vitro (Svensson et al., 2004), a process at
least in part dependent upon infection-modulated levels of the
chemokine CCL8 (Nguyen Hoang et al., 2010). The precise mech-
anisms by which infection itself enhances the capacity for stromal
cells to support rDC induction during chronic inflammation are
not known, but as stromal cells are targets of Leishmania infection
(Bogdan et al., 2000) it is feasible that direct parasite modulation
of stromal cell function may represent a strategy for manipulat-
ing host defense mechanisms in favor of the invading pathogen
(Svensson and Kaye, 2006). Whether similar alterations in stromal
cells occur during other parasitic infections with an abundance
of CD11clorDCs (Li et al., 2011; Smith et al., 2011), and whether
rDCs are associated with chronic infection by viral or bacterial
pathogens will require further investigation.
As stromal cells from organs considered mucosal (Li et al., 2008;
Huang et al., 2009) or with specialized properties related to tol-
erance induction (Xia et al., 2008) have been reported to induce
rDCs, it is possible that this is a generalized feature of stromal
populations from these sites. It is not yet known whether stromal
cells from other mucosal organs, such as the skin or intestine, are
specialized for the induction of rDCs.
MECHANISMS OF rDC INDUCTION BY STROMAL CELLS
Unlike the relatively conserved phenotypic and functional charac-
teristics of rDCs, there are multiple reported mechanisms by which
stromal cells induce these cells. Physical contact between splenic
stromal cells and mature cDCs has been shown to be required
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for their polarization toward a rDC phenotype, in a process also
dependent on fibronectin (Zhang et al., 2004). However, kidney
stromal cells can induce rDCs by a process that does not require
cell-cell contact (Huang et al., 2009), indicating heterogeneity in
the mechanisms underlying stromal cell-induced rDC differenti-
ation. This is perhaps not surprising given the heterogeneity in
stromal cell populations themselves, as shown clearly by recent
transcriptional analysis of stromal cell subsets within lymphoid
tissue (Malhotra et al., 2012).
Diverse stromal cell-derived products such as IL-6 (Huang et al.,
2009), CCL8 and CXCL12 (Nguyen Hoang et al., 2010), TGFβ (Li
et al., 2008), and M-CSF (Xia et al., 2008) have been reported to
impact upon the stromal cell induction of rDCs, but it is unclear as
to whether redundancy exists in this system. In addition to rDCs
being producers of PGE2 and IL-10, the release of these media-
tors by stromal cells has also been implicated in their generation,
with splenic endothelial-produced IL-10 (Tang et al., 2006) and
tumor stroma-derived PGE2 (Liu et al., 2009) playing a role in the
induction of rDC populations.
A potent immunoregulatory circuit endowing human DCs
with IL-27-dependent regulatory potential was recently described
(Ilarregui et al., 2009), relying on the carbohydrate-binding pro-
tein Galectin-1. As Galectin-1 is expressed by stromal cells (Jung
et al., 2007), this raises the intriguing possibility that stromal
populations are also capable of delivering signals that skew con-
ventional human DCs toward regulatory capacity, in addition to
the differentiation of specific rDC populations.
FUTURE QUESTIONS
As evidenced by this short review, there is still much to be revealed
regarding the precise mechanisms by which stromal cells induce
the differentiation and/or expansion of rDCs (Figure 1). Indeed
there are large gaps in our knowledge regarding the precise identity
of rDCs, whether subsets of these cells exist in vivo and the lineage
relationship of rDCs to conventional DC populations. Transcrip-
tional and epigenetic profiling of rDCs from a multitude of tissue
sites and disease states will allow for these questions to begin to
be addressed. As many of the mediators previously reported to
be important for rDC generation are produced widely within the
immune system, it is important to determine how they contribute
to the generation of rDCs within a defined tissue microenviron-
ment. As it is likely that a multitude of synergistic signals underlie
the induction of rDCs by stromal cells, revealing the extent of
redundancy in this system will be key in finding pathways essen-
tial for rDC induction by stromal cells. In addition, extending
our knowledge of the processes by which pathogens, vaccina-
tion, or chronic inflammation can modulate stromal cell function,
and thus favor or suppress rDC induction in vivo will be crucial
when considering therapeutic strategies aimed at manipulating
rDC abundance or function.
Furthermore, a more detailed analysis of the stromal microen-
vironment that supports rDC generation in vitro will provide
clues as to novel mechanisms responsible for their in vivo induc-
tion. This type of analysis has already been performed for splenic
stromal cell populations capable of inducing immature DC pop-
ulations in vitro (Despars et al., 2008), identifying gene sig-
natures associated with this functional capacity. Extending this
approach to rDC induction will likely reveal much useful data in
this area.
More fundamentally, it is essential that we gain a much deeper
understanding of the stromal cell populations capable of rDC
induction in vivo. Even within the same organ it would appear
that diverse stromal populations such as fibroblasts (Svensson
et al., 2004) and endothelial cells (Tang et al., 2006) are capa-
ble of rDC induction. Clarity on whether distinct differences in
stromal cells both within and between organs results in a dif-
fering capacity for rDC induction, or alternative mechanisms by
which induction occurs, will likely reveal much about the biologi-
cal processes required for stromal cells to induce rDC populations.
Key to this may be identification of the tissue specific niches for
rDC development (as this will define the local stromal cell popu-
lation) coupled to transcriptional and/or proteomic analysis of
the stromal cells at such sites. In particular the application of
advanced imaging techniques such as intravital microscopy or
whole mount histology could be applied to identifying stromal
niches for rDC generation in situ, allowing for the visualization
of the distinct microenvironments that facilitate the induction of
these cells. However these approaches will necessitate the develop-
ment of specific tools for the identification of rDCs in vivo. Such
experiments are also likely to challenge the conclusions drawn
from conventional experimental approaches.
To bring clarity to the field, the following approaches should
therefore be taken to address the major outstanding research
questions regarding stromal cell-induced rDCs:
– Transcriptional and epigenetic analysis of stromal-induced
rDCs from distinct tissues to determine whether subsets exist
and their relationship to cDCs.
– Imaging approaches to visualize the stromal cell-rDC niche
in vivo, which will require the development of new tools for
rDC identification.
– Transcriptional and epigenetic analysis of stromal cells capable
of rDC induction, specifically comparing these profiles to those
of stromal cells from distinct tissues and/or disease states.
Extending our knowledge of both rDCs and the stromal cells
that induce them may allow for the potential therapeutic benefits
of this immunoregulatory axis to be realized.
HARNESSING STROMAL CELL NICHES FOR THERAPEUTIC
IMMUNE REGULATION
With patient-specific pro-inflammatory DC infusions effective in
phase III trials for prostate cancer (Kantoff et al., 2010), the use
of myeloid cell populations to modulate immune responses in
humans is rapidly becoming a clinical reality. Applying this ratio-
nale to the design of alternative therapeutic myeloid cell infusions
aimed instead at repressing immune responses is already under
close scrutiny (Kalantari et al., 2011; Lutz, 2012), with progress
in this area likely soon. As stromal cell-induced rDCs are potent
negative regulators of inflammation and improve outcome in pre-
clinical models of hepatic and pulmonary insult (Li et al., 2008;
Xia et al., 2008), such cell populations – once characterized fully
in humans – would provide a promising candidate for therapeutic
infusion.
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Although clearly feasible, the ex vivo expansion of myeloid
cell populations for infusion has disadvantages. Instead, har-
nessing the capacity for stromal cells to regulate rDC induc-
tion by specifically targeting them for functional modulation
in vivo could provide a method to enhance rDC induction for
the amelioration of autoimmune or inflammatory disease, or
conversely repress rDC induction during the immunosuppres-
sion associated with chronic infection and cancer. Stromal tar-
geting approaches have already attracted much interest in the
oncology field (Engels et al., 2012). Experimental therapeutics
have included the targeting of potent cytotoxic agents to tumor
stroma by conjugation to a collagen IV-specific monoclonal anti-
body (Yasunaga et al., 2011), specific enzymatic degradation
of tumor stroma to enhance stromal remodeling (Provenzano
et al., 2012), and therapeutic ablation of cancer stromal cells in
murine tumor models (Kraman et al., 2010), but stromal target-
ing approaches are not usually considered in other therapeutic
contexts.
By expanding our knowledge regarding the detailed mecha-
nisms underlying stromal cell – regulatory dendritic cell interac-
tions, we may advance one step closer to the ultimate goal of subtly
manipulating immune function by targeting stromal cells within
an inflammatory microenvironment.
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